Not exact matches
Dr. Gnjatic's research focuses on
human antigen - specific immune responses to tumor antigens, in an attempt to
define new targets for the development of
cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.
A better understanding of the mutations that cause
human cancer, they said, will help to
define the best strategies for reducing
cancer deaths.
In
humans, iRhoms have been implicated in EGFR - mediated keratinocyte proliferation and
cancer growth, but the molecular mechanisms underlying these biological functions have not been well
defined.»
They have become a valuable resource for biologists, enabling momentous scientific breakthroughs including the development of the polio vaccine the Nobel Prize winning studies
defining the role of telomerase in aging, and research on the causative role of
human papillomavirus (HPV) in some types of cervical
cancer.
«We are at a point in our research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to
define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in
Cancer Research and co-leader of the
Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of
Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine.
As part of the precision medicine initiative at the
Cancer Institute of New Jersey, investigators — which include colleagues from Rutgers Robert Wood Johnson Medical School and RUCDR Infinite Biologics, the world's largest university - based biorepository, located within the
Human Genetics Institute of New Jersey — wanted to
define the relationship of ERBB2 alterations in the pleomorphic form of the disease.
Findings from basic research, such as studies of
cancer cells in the laboratory, can ultimately
define research questions to study in
humans, such as helping to identify drugs to test in clinical trials.
Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung
cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as
defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta -
human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.
Given that drugs derived from JQ1 are already being tested in
cancer clinical trials, their safety and efficacy in
humans are already being
defined.
Dr. Sawyer's more recent work in prostate
cancer has
defined critical signaling pathways for disease initiation and progression through studies in mouse models and
human tissues.
These mice were created and deposited by The Pleiades Promoter Project (Centre for Molecular Medicine and Therapeutics, University of British Columbia); their goal is to generate 160 fully characterized,
human DNA promoters of less than 4 kb (MiniPromoters) to drive gene expression in
defined brain regions of therapeutic interest for studying disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (Lou Gehrig's disease), Multiple Sclerosis, Spinocerebellar Ataxia, Depression, Autism, and
Cancer.
Colon
cancer is
defined as a
cancer of large intestine, the final part of a
human digestive tract.
It covers the link between diet and disease in the Western world (all major diseases, including
cancer, heart disease, obesity, stroke and dementia) and towards a greater knowledge of what can be
defined as the optimal
human diet.